share_log

Longevity Biomedical, Inc. And Denali Capital Acquisition Corp. Announce Business Combination

Longevity Biomedical, Inc. And Denali Capital Acquisition Corp. Announce Business Combination

長壽生醫股份有限公司與德納利資本收購股份有限公司宣佈業務合
Benzinga Real-time News ·  2023/01/26 06:35
  • Longevity Biomedical is focused on developing and acquiring new technologies spanning therapeutics, health monitoring and digital health solutions to become a leading provider of longevity-related products and services designed to increase health span for the rapidly growing global aging population.
  • Late-stage, diversified pipeline of therapeutic candidates across ophthalmology, cardiovascular disease and soft tissue reconstruction and repair.
  • Total proceeds expected to bring minimum pro forma cash balance of $30 million with cash runway into 2025.
  • Near-term clinical milestones include Phase 3 start for LBI-201 for Ischemic stroke, Phase 2 data for LBI-101 for soft-tissue reconstruction, Phase 2 start for LBI-001 in retinal vein occlusion, and completion of preclinical and formulation studies for LBI-002 in corneal blindness.
  • Seasoned management team of medtech and biopharmaceutical veterans with track record of acquiring, developing and commercializing novel technologies.
  • Post-combination company to list on Nasdaq under ticker symbol "LBIO."
  • Business combination expected to close in Q2 2023.
  • 長壽生物醫療專注於開發和獲取涵蓋治療、健康監測和數字健康解決方案的新技術，成為與長壽相關的產品和服務的領先提供商，旨在為快速增長的全球老齡化人口增加健康壽命。
  • 眼科、心血管疾病和軟組織重建和修復的晚期、多樣化的候選治療流水線。
  • 預計總收益將使預計現金餘額至少達到3000萬美元，現金跑道將持續到2025年。
  • 近期的臨床里程碑包括用於缺血性中風的LBI-201的第三階段開始，用於軟組織重建的LBI-101的第二階段數據，用於視網膜靜脈阻塞的LBI-001的第二階段開始，以及用於角膜失明的LBI-002的臨床前和配方研究的完成。
  • 經驗豐富的醫療技術和生物製藥資深管理團隊，擁有獲取、開發和商業化新技術的記錄。
  • 合併後的公司將在納斯達克上市，股票代碼為“LBIO”。
  • 業務合併預計將於2023年第二季度完成。
声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論